Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.

4D Pharma Research Ltd., a subsidiary of 4D Pharma Plc, is a company headquartered in Aberdeen, UK, that engages in research and experimental development on biotechnology.

Susavion Biosciences, Inc., is a privately-owned company that was formed to advance technology based on discovery of multi-valent, bio-active peptides that mimic carbohydrate ligands of lectin-type receptors suitable for use as therapeutic modulators of the immune system.

Clinique La Prairie offers the most advanced health and wellness programs, in absolute luxury.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Entelos is the leading provider of predictive biosimulation for drug discovery and development. We provide advanced biosimulation capabilities that make discovery more efficient and increase clinical success. For over 15 years, we have enabled R&D organizations to predict better paths to success by simulating systems biology. Our solutions include mechanism-based, mathematical models; virtual patients and populations; biosimulation software; and biosimulation expertise.

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Eyegene, Inc. engages in the research and development of pharmaceutical products. Its products include curing technologies and vaccines for diabetic retinopathy, decubitus ulcer, cervical cancer, and adjuvant immunotherapy. The company was founded on June 23, 2000 and is headquartered in Seoul, South Korea.

Part of Lonza Group AG, Lonza Ltd. is a company headquartered in Basel, Switzerland, that supplies chemicals for pharmacy industry.

Acuitas Therapeutics, Inc. is a private company headquartered in Vancouver, BC, Canada, that develops therapeutics based on RNA interference. Thomas Madden is currently the CEO of the firm.\nThe company says this about itself: Acuitas Therapeutics is a private bio technology company located in Vancouver, British Columbia, Canada developing novel LNP carriers for mRNA and other nucleic acid therapeutics, including technology developed under limited license from Arbutus Biopharma Corporation.

Korea Food Research Institute is a global food R&D institution that contributes to the health of Korea.

Manufactures and distributes pharmaceutical products

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia.

Immunepath, Inc. is an American private company that operates a biotechnology company that develops stem cell based therapeutics.

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.

Genome Pharmaceuticals Institute Co. Ltd. is a

InCytu is a therapeutic device engineering company developing immunotherapeutic and tissue regeneration products to transform personalized medicine. Founded in 2007 and lead by a strong management team, the cornerstone of InCytu's transformative technology platform was developed by Prof. David Mooney at Harvard University. The Company's first products revolve around the Cellarium™ system, a family of intelligent bioresorbable materials which are formulated and programmed to manipulate the immune system or rapidly heal and regenerate damaged or diseased tissue.